NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/03/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization138.04 mln
Float93.21 mln
Earnings Date11/10/2026
1-Year Forecast
3.17
Transformational upside
Relative Strength
94
/ 100
Top performer
Debt / Equity
1.83
High leverage
ROE
-609
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Inovio Pharmaceuticals is a biotechnology company based in Plymouth Meeting, Pennsylvania, focused on developing DNA-based medicines to treat and prevent diseases linked to HPV, cancer, and infectious conditions. The company uses its proprietary platform to design and deliver these treatments, with several candidates currently in clinical trials targeting conditions such as recurrent respiratory papillomatosis, cervical disease, glioblastoma, Ebola, COVID-19, and HIV. Inovio works alongside a broad network of partners, including AstraZeneca, Regeneron Pharmaceuticals, the National Institutes of Health, and several academic institutions.
